Table 1 Characteristics of included randomized controlled trials. PRP platelet-rich plasma
Authors | Publish year | Male % (PRP+/PRP−) | Mean age (PRP+/PRP−) | Shoulders analysed (PRP+/PRP−) | Minimum imaging follow-up, months | Minimum clinical follow-up, months |
|---|---|---|---|---|---|---|
Castricini et al. [25] | 2011 | 40 (17/23) | (55.5/55.2) | 88 (43/45) | 16 | 16 |
Randelli et al. [31] | 2011 | 21 (8/13) | (61.3/59.5) | 45 (22/23) | 12 | 12 |
Gumina et al. [27] | 2012 | 41 (20/21) | 61 (60/63) | 76 (39/37) | 12 | 12 |
Weber et al. [35] | 2012 | 36 (20/16) | (59.7/64.5) | 59 (29/30) | 12 | 12 |
Jo et al. [28] | 2013 | 24 (10/14) | (64.2/61.9) | 47 (24/23) | 9 | 12 |
Ruiz-Moneo et al. [33] | 2013 | 25 (14/11) | (56/55) | 63 (32/31) | 12 | 12 |
Malavolta et al. [30] | 2014 | 17 (8/9) | (55.3/54.1) | 54 (27/27) | 12 | 12 |
Sánchez Márquez et al. [34] | 2011 | 8 (NR/NR) | 65 (NR/NR) | 28 (14/14) | 12 | 12 |
Rodeo et al. [32] | 2012 | 44 (23/21) | (58.9/57.2) | 67 (35/32) | 3 | 12 |
Flury et al. [26] | 2016 | 38(18/20) | 58.9 /57.8 | 103 (49/54) | 24 | 24 |
Holtby et al. [9] | 2016 | 41(20/21) | 59/59 | 74 (36/38) | 6 | 6 |
Pandey et al. [10] | 2016 | 74(38/36) | 54.8 /54.1 | 102 (52/50) | 24(12) | 24(12) |
Jo et al. [29] | 2015 | 17(8/9) | 60.8/60.92 | 74(37/37) | 12 | 12 |